A biosimilar is a biological product that is approved based on data demonstrating high similarity to an FDA-approved biological product (reference product).
Annual mammography screening, used by most patients, yields smaller and less advanced cancers.
Genetic testing provided important information beyond personal and family history.
Effects of chemotherapy found to be more transient in comparison.
Findings seen among postmenopausal breast cancer patients regardless of activity level prediagnosis.
Rates for breast, cervical, colorectal cancer screening lower compared with women without diabetes.
Palliative care and end-of-life needs were not addressed for approximately 40% of simulated patients who would have been eligible for this approach.
Incidence of composite cardiovascular events decreased across increasing total MET hours/week.
Rates of grade 3/4 AEs and dose reductions/interruptions associated with CDK4/6 + AI therapy were higher in those 75 years and older compared with younger patients.
An exploratory analysis showed that the VENTANA PD-L1 SP142 IHC assay had subpar concordance with 2 other PD-L1 IHC assays that are not approved for metastatic TNBC.
Pace of decline slowed from 1.9 percent during 1998 to 2011 to 1.3 percent during 2011 to 2017.
In TAILORx, 84% of patients with a high recurrence score were treated with chemotherapy containing a taxane and/or an anthracycline prior to endocrine therapy.
Results of the YoungPearl study revealed that patient-reported QoL scores were high for palbociclib plus endocrine therapy.
Results of MONARCH-2 showed a statistically significant and clinically meaningful improvement in overall survival with abemaciclib plus fulvestrant.
At 3-year follow-up, the mean LVEF was over 60% in both study arms.
The precision of the targeted methylation sequencing assay for localizing the cancer tissue of origin was reported to be 89%.
Pembrolizumab monotherapy does not improve overall survival (OS) compared with single-agent chemotherapy among women with metastatic triple negative breast cancer (mTNBC).
Investigators evaluated the impact doxorubicin and/or trastuzumab have on diastolic function and the association between diastolic function and systolic dysfunction.
An evaluation of patient education materials on chemotherapy for breast cancer revealed that many do not meet NIH recommendations.
Clinical characteristics, undertreatment correlated with 63.3 percent excess mortality rate for men.